Johnson Redbook Index Reflects Sluggish US Same-Store Sales
Subdued US same-store sales are not a favorable indicator for department stores. In 1Q15, which ended May 2, 2015, Macy’s (M) reported a 0.7% fall in same-store sales.
The Conference Board Consumer Confidence Index (or CCI) fell sharply to 90.9 in July. The CCI rose in June to 99.8 from 94.6 in May.
The Bloomberg Consumer Comfort Index fell to 40.5 in the week ended July 26, from 42.4 in the week before. This is the fourth week of decline and the second lowest level since November 2014.
The US jobless claims for the week ended July 25 increased 12,000 to 267,000 from the previous week. This was better than the consensus economists’ estimate of 272,000.
After a soft start in the first quarter of 2015, US GDP (gross domestic product) increased 2.3% in the second quarter of 2015. It was below the consensus economist estimate of 2.9%.
Panera’s (PNRA) investors are focusing on more important growth initiatives at the company. Panera 2.0 is one of the key initiatives that has kept investors hooked on the stock.
To answer this question, we’ll take a look at Panera’s (PNRA) recent same-store sales growth performance. Almost 88% of the company’s revenue comes from company-owned cafes
The long-awaited update from Panera’s (PNRA) July 28 earnings call was the progress of Panera 2.0. The company has made “significant” investments in Panera 2.0.
On July 28, Panera’s (PNRA) management gave some color on how the plan should affect same-store sales growth over the long term.
In this post, we’ll compare Panera’s valuation with that of its peers and see if Panera looks expensive, cheap, or fairly valued.
In this part, we’ll look at how the company’s valuation PE (price-to-earnings multiple) affects Panera’s stock price.
Panera Bread (PNRA) reported its 2Q15 earnings on July 28, 2015, after the market closed. Shares popped almost 15% from $186.99 to $202.27.
In the 1Q15 earnings call, CVS raised its full-year EPS guidance from $5.05–$5.19 to $5.08–$5.19. That represents a growth rate of 13%–15.5% over 2014 EPS levels.
CVS Health (CVS) stock is up almost 14% this year. It’s also up by 7.3% since the Target deal was announced on June 15 and by 8.4% since it announced its intent to acquire Omnicare on May 21.
CVS Health is targeting a payout ratio of 35% by 2018. Dividend per share would come in at $2.13 in 2018, according to the company’s guidance CAGR of 18% from 2014–2018.
CVS is the largest specialty pharmacy in the United States. Specialty sales came in at $31 billion in 2014 and are expected to rise to $37 billion this year.
CVS Health’s (CVS) profitability is falling. Its gross margins have been on the decline, partly due to a shift in the sales mix in its Pharmacy Services segment.
CVS Health (CVS) is planning to increase its net retail store count by about 150 in 2015. In 1Q15, CVS added 28 net new stores.
CVS Health (CVS) expects 2Q15 same-store sales to come in between -1.25% and 0.25%. Comps were affected by the discontinuation of tobacco sales, which reduced front store sales comps 8%.
CVS Health (CVS) expects Retail Pharmacy sales growth between 0.5% and 2% year-over-year in 2Q15. Total same-store sales are expected to be in the range of -1.25% to 0.25%.
But if I knew how to manage my portfolio safer and smarter than most hedge fund managers, I could realistically grow my wealth.